Building healthier futures powered by thoughtful science

We are a highly focused, research-driven biopharmaceutical company working in rare diseases. We're exploring the potential of cutting-edge science as a subsidiary of Nippon Shinyaku Co., Ltd. In Japan.

Advancing rare disease research

Inspired by our own families, as well as the individuals we aim to provide with treatment, NS Pharma is conducting advanced research in rare diseases, including exon-skipping technology, to offer new, effective treatment options for Duchenne. We’re also developing JAK1 inhibition for the potential treatment of eosinophilic granulomatosis with polyangiitis (EGPA).

Therapeutic areas

NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.

Scientific approaches

Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.

Therapeutic areas

NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.

Scientific approaches

Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.

From our blog

News / February 7, 2025

NS Pharma and MiNA Therapeutics: Meeting Unmet Medical Needs Through Partnership and Co-creation

News / February 7, 2025

The Power of Shinrai: Trust-Driven Leadership Is Driving Growth in Rare Disease Breakthroughs

Press Release / January 27, 2025

Nippon Shinyaku and AB2 BIO enter into an Option Agreement for Commercialization of Tadekinig alfa for the treatment of NLRC4 mutation and XIAP deficiency in the U.S.

News / February 7, 2025

NS Pharma and MiNA Therapeutics: Meeting Unmet Medical Needs Through Partnership and Co-creation

News / February 7, 2025

The Power of Shinrai: Trust-Driven Leadership Is Driving Growth in Rare Disease Breakthroughs

Press Release / January 27, 2025

Nippon Shinyaku and AB2 BIO enter into an Option Agreement for Commercialization of Tadekinig alfa for the treatment of NLRC4 mutation and XIAP deficiency in the U.S.

Social media

Chocolate, camaraderie & a little extra sweetness!

Today, the team took a well-deserved break to indulge in some sweet treats together. Every day is a good day in the NSP office—but we won’t deny that chocolate fondue makes it even better!

Happy #ValentinesDay! 💕

#TeamSpirit https://x.com/NSPharmaInc/status/1890416587619885234/photo/1

Happy #InternationalDayOfWomenAndGirlsInScience!

Today, we celebrate the brilliant #WomenInScience who push the boundaries of innovation and discovery every day! 💙

A BIG shout-out to all the #WomenInSTEM. Let's continue to break barriers & pave the way for the next generation! https://x.com/NSPharmaInc/status/1889328894890623177/photo/1

Meet Lucy – Our New Manager of #CorporateCommunications! 🎉

With 8+ years in content creation & corporate brand strategy, she brings a fresh & dynamic approach to the team.

In her free time, Lucy enjoys horseback riding, traveling and hiking with her dog!🐶

#Welcome, Lucy! 💙 https://x.com/NSPharmaInc/status/1887879311241150558/photo/1

Shining a Light on #WorldCancerDay 🌍

This is a cause that is very close to our hearts and today, we stand united to raise awareness and inspire action in the fight against cancer.

Together, let’s create a healthier, brighter future. 💪💙

#UnitedByUnique #Cancer https://x.com/NSPharmaInc/status/1886792317136146907/photo/1

We're kicking off the first @CureDuchenne Workshop of 2025 in Kansas City tomorrow!💙

📍 Kansas City, MO
🗓️ February 1, 2025
🕘 8:00 AM – 4:00 PM

We look forward to seeing you there for a wholesome day of learning and connection!

#Duchenne #CureDuchenneCares #StrongerTogether https://x.com/NSPharmaInc/status/1885342279738733002/photo/1

Rare diseases demand innovation🌟

For those living with NLRC4 mutation and XIAP deficiency, the wait for effective treatments has been long and challenging - but change IS on the horizon!

Read the press release: https://ow.ly/Q7U950UNUai

#RareDiseases #AutoimmuneDisease https://x.com/NSPharmaInc/status/1883913697795494004/photo/1

Another significant step forward for the Duchenne community! This recognition moves us closer to delivering meaningful progress and hope to those impacted. 🚀

Read more about it here: https://www.nspharma.com/press-releases

#Duchenne #RareDiseases #DMD https://x.com/NSPharmaInc/status/1882470316904939859/photo/1